Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD40 Ligand

CD40 Ligand

Brief Information

Name:CD40 ligand
Target Synonym:CD154 Antigen,HCD40L,CD154,TNFSF5,CD40L,CD40 ligand, soluble form,CD40 ligand, membrane form,Tumor necrosis factor ligand superfamily member 5,T-cell antigen Gp39,CD40-L,CD40LG,TNF-Related Activation Protein,Tumor Necrosis Factor (Ligand) Superfamily Member 5,T-B Cell-Activating Molecule,T-BAM,HIGM1,Gp39,IMD3,IGM,CD40 Ligand,CD40 Antigen Ligand,TRAP,Tumor Necrosis Factor (Ligand) Superfamily, Member 5 (Hyper-IgM Syndrome),Hyper-IgM Syndrome,sCD40L
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:12
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

Part of Bioactivity data

CDL-H5269-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS analysis shows that Human CD40 Ligand, Fc Tag (active trimer) (MALS verified) (Cat. No. CDL-H5269) can bind to 293T-CD40 cells surface CD40. The concentration of Human CD40 Ligand is 0.3 μg/mL (Routinely tested).

CDL-H5269-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Human CD40 Ligand, Fc Tag (active trimer) (MALS verified) (Cat. No. CDL-H5269) stimulates secretion of IL-6 by human B cells. The ED50 for this effect is 9.68-11.48 ng/mL in the presence of 5 ng/mL of Recombinant Human IL‑4 (Routinely tested).


Loaded Human CD40, Fc Tag (Cat. No. CD0-H5253) on Protein A Biosensor, can bind Human CD40 Ligand, His,Flag Tag (Cat. No. CDL-H52Db) with an affinity constant of 1.58 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Biotinylated Mouse CD40 Ligand, His,AvitagBiotinylated Mouse CD40 Ligand, His,Avitag (Cat. No. CDL-M82H5) ELISA bioactivity

Immobilized Mouse CD40, His Tag (Cat. No. TN5-M52H8) at 5 μg/mL (100 μL/well) can bind Biotinylated Mouse CD40 Ligand, His,Avitag (Cat. No. CDL-M82H5) with a linear range of 0.5-16 ng/mL (QC tested).

Synonym Name



CD40 ligand is also known as CD40L, CD154, TNFSF5 and T-cell antigen Gp39, is a single-pass type I I membrane protein which belongs to the TNF superfamily of molecules. CD40 ligand is expressed predominantly on activated CD4+ T lymphocytes, and also found in other types of cells, including platelets, mast cells, macrophages, basophils, NK cells, B lymphocytes, as well as non-haematopoietic cells (smooth muscle cells, endothelial cells, and epithelial cells). Although all monomeric, dimeric and trimeric forms of soluble CD40 ligand can bind to CD40, the trimeric form of soluble CD40 ligand has the most potent biological activity through oligomerization of cell surface CD40, a common feature of TNF receptor family members.CD40 ligand binds to CD40 on antigen-presenting cells (APC), which leads to many effects depending on the target cell type. In general, CD40 ligand plays the role of a costimulatory molecule and induces activation in APC in association with T cell receptor stimulation by MHC molecules on the APC. In total CD40 ligand has three binding partners: CD40, α5β1 integrin and αIIbβ3. CD40 ligand regulates B cell function by engaging CD40 on the B cell surface. A defect in this gene results in an inability to undergo immunoglobulin class switch and is associated with hyper IgM syndrome.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Letolizumab BMS-986004; BMS2h-572-633-CT-L2 Phase 2 Clinical Bristol-Myers Squibb Company Purpura, Thrombocytopenic, Idiopathic Details
AdCD40L Phase 2 Clinical Uppsala University Urinary Bladder Neoplasms; Melanoma Details
APB-A1 APB-A1 Phase 1 Clinical AprilBio Co Ltd Neuromyelitis Optica Details
rVV-740CTA vaccine (University Hospital Basel) rVV-740CTA Phase 1 Clinical University Hospital Basel Breast Neoplasms Details
BIIB-063 BIIB-063 Phase 1 Clinical Biogen Inc Sjogren's Syndrome Details
Anti-CD40L antibody (Bristol-Myers Squibb) Phase 2 Clinical Bristol-Myers Squibb Company Immunologic Deficiency Syndromes Details
Delolimogene mupadenorepvec LOAd-703 Phase 2 Clinical Lokon Pharma, Uppsala University Biliary Tract Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Melanoma Details
INX-021 INX-021; SAR-441344 Phase 2 Clinical Immunext Multiple Sclerosis; Lupus Erythematosus, Systemic; Sjogren-Larsson Syndrome Details
iHIVARNA-01 iHIVARNA-01 Phase 2 Clinical Idibaps HIV Infections Details
MEM-288 MEM-288 Phase 1 Clinical Memgen Head and Neck Neoplasms; Solid tumours; Carcinoma, Merkel Cell; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Melanoma Details
Dazodalibep MEDI-4920; UNII-HN5US76BWF; WHO-11399; HZN-4920(Horizon Therapeutics); VIB-4920 Phase 2 Clinical Horizon Therapeutics Plc, Medimmune Llc Rejection of renal transplantation; Arthritis, Rheumatoid; Sjogren's Syndrome; Sjogren-Larsson Syndrome Details
Dapirolizumab pegol Anti-CD40L-Fab; Anti-CD40L-Fab-PEG; CDP-7657; CD40L - Fab; BIIB-133 Phase 3 Clinical Biogen Inc, Ucb Autoimmune Diseases; Connective Tissue Diseases; Lupus Erythematosus, Systemic Details
AT-1501 AT-1501 Phase 2 Clinical Als Therapy Development Institute, Anelixis Therapeutics Llc Diabetes Mellitus, Type 1; Rejection of renal transplantation; Glomerulonephritis, IGA; Amyotrophic Lateral Sclerosis Details

This web search service is supported by Google Inc.

Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message